By Fineline Cube 
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ: NXTC) announced a strategic collaboration to co – develop SIM0505, a novel CDH6 – targeted antibody – drug conjugate (ADC) for solid tumors.
Collaboration Terms
Under the agreement, NextCure secures global rights (excluding Greater China) for SIM0505’s development and commercialization, while Simcere Zaiming retains rights in Greater China. The drug is currently undergoing Phase I trials in China, with US studies expected to commence in Q3 2025. Initial clinical data is anticipated in the first half of 2026.
Drug Profile and Technology Exchange
SIM0505 features Simcere Zaiming’s proprietary topoisomerase I inhibitor (TOPOi) payload, demonstrating a favorable safety profile and potent anti – tumor activity. Additionally, NextCure licenses Simcere Zaiming’s linker technology and TOPOi payload platform to develop another novel ADC. Simcere Zaiming retains Greater China rights to this second program.
Financial Terms
The deal has a potential value of up to USD 745 million, including upfront payments, development and sales milestone payments, and tiered royalties on ex – Greater China net sales.-Fineline Info & Tech